“Potent” antibodies provide protection from COVID-19 in cell cultures, finds study
Newly discovered antibodies found in the blood of recovered COVID-19 patients could provide robust protection against SARS-CoV-2, say researchers.
List view / Grid view
Newly discovered antibodies found in the blood of recovered COVID-19 patients could provide robust protection against SARS-CoV-2, say researchers.
Following an analysis of scientific literature, researchers say that COVID-19 may affect the entire nervous system, including the brain, spinal cord, nerves and muscles.
New research indicates COVID-19 could trigger the development of diabetes in healthy people, prompting experts to establish a registry for COVID-19 and diabetes data.
A group of small molecules called naphthalene-based PLpro inhibitors have been shown to block the activity of a SARS-CoV-2 protein, demonstrating potential as COVID-19 therapeutics.
Dr Jing Watnick discusses how lessons learnt from cancer immunotherapy treatments could be applied to the development of COVID-19 therapies.
Researchers have suggested that neutrophils, which contribute to the development of ARDS in COVID-19 patients, could be diverted from the lungs by rod-shaped particles in a new form of treatment.
Researchers reveal the main protease (Mpro) of SARS-CoV-2 is highly sensitive to disruption, therefore Mpro inhibitors could be a potential COVID-19 therapeutic.
Researchers used computational tools to identify regions of the SARS-CoV-2 virus that could potentially provide a safe and long-term immune response.
The team found microglia and CD8 T cells were vital to protecting neurons from vesicular stomatitis virus (VSV) infection and suggest loss of taste and smell in COVID-19 could be due to a certain mechanism of infection.
Pre-clinical testing of the COVIDTRAP™ (STI-4398) protein and STI-1499 antibody reveal they can inhibit SARS-CoV-2 from infecting cells.
Sarah Ahmed explores how environmental factors may be causing the disparity in numbers of cases between different countries.
Mass spectrometry revealed biomarkers that could be used as drug targets for developing novel therapeutics or to predict whether a patient with COVID-19 will become severely ill.
Researchers found there is a gradient of SARS-CoV-2 infectivity down the airway and that the severe pneumonia symptoms may be caused by aspiration of oral contents into the lungs.
Researchers in the US describe how they utilised previously published scientific literature to guide the design of their potential COVID-19 vaccine.
Researchers develop a knock-in mouse expressing human angiotensin-converting enzyme 2 (hACE2) to model SARS-CoV-2 infection for research and therapeutic or vaccine testing.